Pamrevlumab for the treatment of idiopathic pulmonary fibrosis

References

• Antoniou KM , Margaritopoulos GA , Tomassetti S , et al. Interstitial lung disease. Eur Respir Rev. 2014;23(131):40–54.
   PubMedGoogle Scholar
• Ley B , Collard HR , King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Selman M , King TE , Pardo A , et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–151.
   PubMed Web of Science ®Google Scholar
• King TE , Tooze JA , Schwarz MI , et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171–1181.
   PubMed Web of Science ®Google Scholar
• Raghu G , Weycker D , Edelsberg J , et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–816.
   PubMed Web of Science ®Google Scholar
• Richeldi L , Cottin V , Du Bois RM , et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Raghu G , Remy-Jardin M , Myers JL , et al. Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Hutchenreuther J , Vincent K , Norley C , et al. Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma. Matrix Biol. 2018;74:52–61.
   PubMed Web of Science ®Google Scholar
• Yeger H , Perbal B. CCN family of proteins: critical modulators of the tumor cell microenvironment. J Cell Commun Signal. 2016;10(3):229–240.
   PubMed Web of Science ®Google Scholar
• Richeldi L , Fernández Pérez ER , Costabel U , et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33.
   PubMed Web of Science ®Google Scholar
• Raghu G , Rochwerg B , Zhang Y , et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
   PubMed Web of Science ®Google Scholar
• Conte E , Gili E , Fagone E , et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19.
   PubMed Web of Science ®Google Scholar
• Wollin L , Wex E , Pautsch A , et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–1445.
   PubMed Web of Science ®Google Scholar
• Richeldi L , Du Bois RM , Raghu G , et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• King TE , Bradford WZ , Castro-Bernardini S , et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Rochwerg B , Neupane B , Zhang Y , et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med. 2016;14(1):18.
   PubMedGoogle Scholar
• Costabel U , Inoue Y , Richeldi L , et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–185.
   PubMed Web of Science ®Google Scholar
• Vancheri C , Sebastiani A , Tomassetti S , et al. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respir Med. 2019;156:78–84.
   PubMed Web of Science ®Google Scholar
• Fisher M , Nathan SD , Hill C , et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2017;23(3–b Suppl):S17–S24.
   PubMedGoogle Scholar
• Vancheri C , Kreuter M , Richeldi L , et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356–363.
   PubMed Web of Science ®Google Scholar
• Borie R , Justet A , Beltramo G , et al. Pharmacological management of IPF. Respirology. 2016;21(4):615–625.
   PubMed Web of Science ®Google Scholar
• Lipson KE , Wong C , Teng Y , et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(S1):S1–S24.
   PubMedGoogle Scholar
• Wang Q , Usinger W , Nichols B , et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenes Tissue Repair. 2011;4(1):4.
   PubMedGoogle Scholar
• Maher TM , Wells AU . Lost in translation; From animal models of pulmonary fibrosis to human disease. Respirology. 2009;14:915–916.
   PubMed Web of Science ®Google Scholar
• Brenner MC , Krzyzanski W , Chou JZ , et al. FG-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition. Pharm Res. 2016;33(8):1833–1849.
   PubMed Web of Science ®Google Scholar
• Raghu G , Scholand MB , de Andrade J , et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47(5):1481LP–1491.
   Web of Science ®Google Scholar
• Richeldi L , Fernández Pérez ER , Costabel U , et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25‐33. doi:10.1016/S2213-2600(19)30262-0.
   PubMed Web of Science ®Google Scholar
• Gorina E , Chou J , Sekayan T , et al. PK and PK/PD modeling to inform dosing optimization for pamrevlumab in idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med. 2018;8:25–33.
   Google Scholar
• Neesse A , Frese KK , Bapiro TE , et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013;110(30):12325–12330.
   PubMed Web of Science ®Google Scholar
• Finger EC , Cheng C-F , Williams TR , et al. CTGF is a therapeutic target for metastatic melanoma. Oncogene. 2014;33(9):1093–1100.
   PubMed Web of Science ®Google Scholar
• Lu H , Kojima K , Battula VL , et al. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol. 2014;93(3):485–492.
   PubMed Web of Science ®Google Scholar
• Ohara Y , Chew SH , Misawa N , et al. Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. Oncotarget. 2018;9(26):18494–18509.
   PubMedGoogle Scholar
• Thannickal VJ , Horowitz JC . Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006;3(4):350–356.
   PubMedGoogle Scholar
• Bickelhaupt S , Peschke P , Erbel C , et al. Attenuation and reversal of radiation-induced pulmonary fibrosis in a murine model by an anti-CTGF monoclonal antibody. Int J Radiat Oncol. 2010;78(3):S40.
   Web of Science ®Google Scholar
• Raghu G , Van Den Blink B , Hamblin MJ , et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis a randomized clinical trial. JAMA. 2018;319(22):2299–2307.
   PubMed Web of Science ®Google Scholar
• Maher TM , van der Aar EM , Van de Steen O , et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018;6(8):627–635.
   PubMed Web of Science ®Google Scholar
• Parker JM , Glaspole IN , Lancaster LH , et al. A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;197(1):94–103.
   PubMed Web of Science ®Google Scholar
• Jones MG , Sgalla G , Richeldi L . Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;197:9–10.
   PubMed Web of Science ®Google Scholar
• Flaherty KR , Wells AU , Cottin V , et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;382:779–781.
   Google Scholar
• Distler O , Highland KB , Gahlemann M , et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Behr J , Bendstrup E , Crestani B , et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4(6):445–453.
   PubMed Web of Science ®Google Scholar
• Raghu G , Anstrom KJ , King TE Jr. , et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–1977.
   PubMed Web of Science ®Google Scholar